PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
 
Curr Hypertens Rev. 2013 February; 9(1): 66–75.
Published online 2013 February. doi:  10.2174/1573402111309010010
PMCID: PMC3636518

Evaluation of Blood Pressure Control using a New Arterial Stiffness Parameter, Cardio-ankle Vascular Index (CAVI)

Abstract

Arterial stiffness has been known to be a surrogate marker of arteriosclerosis, and also of vascular function. Pulse wave velocity (PWV) had been the most popular index and was known to be a predictor of cardiovascular events. But, it depends on blood pressure at measuring time. To overcome this problem, cardio-ankle vascular index (CAVI) is developed. CAVI is derived from stiffness parameter β by Hayashi, and the equation of Bramwell-Hill, and is independent from blood pressure at a measuring time. Then, CAVI might reflect the proper change of arterial wall by antihypertensive agents.

CAVI shows high value with aging and in many arteriosclerotic diseases and is also high in persons with main coronary risk factors. Furthermore, CAVI is decreased by an administration of α1 blocker, doxazosin for 2-4 hours, Those results suggested that CAVI reflected the arterial stiffness composed of organic components and of smooth muscle cell contracture. Angiotensin II receptor blocker, olmesartan decreased CAVI much more than that of calcium channel antagonist, amlodipine, even though the rates of decreased blood pressure were almost same. CAVI might differentiate the blood pressure-lowering agents from the point of the effects on proper arterial stiffness.

This paper reviewed the principle and rationale of CAVI, and the possibilities of clinical applications, especially in the studies of hypertension.

Keywords: Cardio-ankle vascular index, arterial stiffness, angiotensin II receptor blockers, calcium channel blocker, hypertension.

INTRODUCTION

The significance of arterial stiffness for the prognosis of cardiovascular diseases is nearly established [1-4]. Arterial stiffness is based on the structural changes occurring prior to plaque or thrombus formation in muscular and elastic vessels. Several methods have been designed to assess arterial stiffness including pulse wave velocity (PWV) [1-7] and augmentation index [8]. As for PWV, there were many methods such as carotid-femoral PWV (cfPWV) [9], heart to femoral PWV(hfPWV)[10] and brachial-ankle pulse wave velocity (baPWV) [11]. And, many data as a surrogate marker of arteriosclerosis had been reported [3-5, 12-15]. However, PWV is known to depend on blood pressure at the time of measurement [16, 17]. Then, the real effects of blood pressure control on the properties of arterial wall had not been accurately evaluated.

In1980, Hayashi et al. [18] proposed the stiffness parameter β = 1n(Ps/Pd).D/[increment]D, where Ps is systolic, Pd is diastolic blood pressure, D is diameter of the artery, and [increment]D is the change in arterial diameter according to blood pressure difference. This value does not depend on the blood pressure, theoretically. Kawasaki et al. [19] tried to measure stiffness parameter β in cervical artery using the echo-phase tracking system. A limitation of the stiffness parameter β is that it is applicable to a local segment of the artery. The cardio-ankle vascular index (CAVI) was developed to measure proper arterial stiffness with some length, according to the theory of stiffness parameter β. This time, CAVI was applied to the artery from the origin of the aorta to the ankle of tibial artery as shown in Fig. (11) [20]. The rationale for the expansion of stiffness β theory at one segment of the artery to some length of the artery composed of various types such as elastic artery and muscular artery, has to be confirmed from various aspects. Until now, many aspects of clinical studies on CAVI seemed to support the rightness of expanding β theory to some length of artery, as shown in Table 11 [21-26].

Fig. (1)
CAVI and its measuring method (Ref. 20). PWV from the heart to the ankle is obtained by measuring the length from the origin of the aorta to the ankle, and by calculating T = tb + tba. Blood pressure is measured at the brachial artery. Ps: systolic blood ...
Table 1.
CAVI in Arteriosclerotic Diseases and in Coronary Risks

Especially, the studies using β1-aderenoceptor blocker and α1-aderenoceptor blocker indicated that CAVI was independent of blood pressure at measuring time, and reflected not only organic stiffness, but also the functional stiffness composed of smooth muscle contracture [24].

This review described the principle of CAVI and reviewed the recent reports about CAVI, focusing on the roles of CAVI in hypertension research.

1. THE PROPERTIES OF CAVI

1) The Principle of CAVI

The CAVI reflects the stiffness of the whole arterial segment comprising the aorta, femoral artery and tibial artery (Fig. 11, from ref.20). This index was originally derived from the stiffness parameter β proposed by Hayashi [18] and Kawasaki et al. [19], and was expanded to some length of the artery with application of modified Bramwell-Hill’s equation [27].

CAVI = a{(2ρ/[increment]P) x ln(Ps/Pd) PWV2} + b ------ CAVI formula

where, Ps is systolic blood pressure, Pd is diastolic blood pressure, PWV is pulse wave velocity from the origin of the aorta to tibial artery at the ankle through the femoral artery, [increment]P is Ps - Pd, ρ is blood density, and a and b are constants.

Theoretically, blood pressure applied must be obtained at each every point from the origin of the aorta to tibial artery at the ankle. The problem is that the blood pressure is increasing from the origin of the aorta to the femoral artery, and is decreasing from the femoral artery to peripheral artery. Conveniently, mean blood pressure of the whole artery could be applied. In place of a mean blood pressure of the whole artery, blood pressure at the brachial artery was applied in CAVI.

Thus, CAVI is originated from the stiffness parameter β = ln(Ps/Pd) . (D/[increment]D). D/[increment]D is calculated from PWV of some length of the artery and [increment]P, in place of diameter change (D/[increment]D) [27].

2) The Rationales of CAVI to be Applied to some Length of Artery and of Independence from Blood Pressure at a Measuring Time

There still remain several questions for CAVI. One is whether it is valid to apply Bramwell–Hill’s equation to the equation of the stiffness parameter β, which is essentially applied to some segment of the artery. Takaki et al. [21] provided the evidence for the validity of CAVI by showing a positive correlation between the stiffness parameter β of the aorta and CAVI (r = 0.67, P <0.01).

Next question is that, the most conspicuous feature of CAVI is theoretical independence of the blood pressure at the time of measurement. However, this has to be proven, experimentally. Several reports [21-24] showed that CAVI is less dependent on blood pressure than PWV. But, these results do not necessarily mean that CAVI is independent of blood pressure at the time of measurement.

We tried to solve this question using a selective β1 receptor blocker, metoprolol as shown in Fig. (2A2A) [24]. When metoprolol was administered to 12 men, systolic and diastolic blood pressure decreased for 6 hours. baPWV decreased accompanying with a decrease in blood pressure as expected, but CAVI did not change. This result indicated that CAVI was not influenced by blood pressure at the time of measurement.

Fig. (2)
Effects of the β1- blocker, metoprolol and α1- blocker, doxazosin on CAVI and baPWV (Ref. 24). When selective β1 -adrenergic blocker metoprolol (80 mg) was administered, both systolic and diastolic blood pressures decrease and ...

Then, CAVI could be used to evaluate the effect of blood pressure control on the proper stiffness of arterial wall.

3) CAVI as a Surrogate Marker of Arteriosclerotic Diseases and Coronary Risk Factors

1) Coronary Arterial Diseases

CAVI of healthy people in Japan without cardiovascular risk factors increases with aging from 20 to 70 years [25]. CAVI of men is higher than that of women in all ages by 0.2.

As for coronary artery disease, CAVI increases as the number of coronary vessels with stenosis (>75%), increases [26]. The cutoff point of CAVI for the presence of coronary stenosis was 8.91 among the patients with a suspicion of ischemic coronary artery disease. Izuhara et al. [28] also reported the multiple logistic analysis revealing that CAVI, but not baPWV was associated with the presence of carotid and coronary arteriosclerosis. And several worker reported that CAVI was high in coronary artery disease [28-31].

Sairaku et al. [31] reported that CAVI was high in acute coronary syndrome and decreased after 6 months. Transient high CAVI might induce or trigger the acute coronary syndrome.

2) Carotid Arteriosclerosis

As for intima-media thickness (IMT) of carotid artery, several workers showed strong correlation between CAVI and IMT, but, plaque score showed much more stronger correlation with CAVI [27-30].

The combination of CAVI and IMT might be a much significant predictor of cerebral thrombosis in highly atherosclerotic patients.

3) Chronic Kidney Diseases

As for chronic kidney disease, there were several reports that CAVI correlated with estimated glomerular filtration rate [32, 33]. CAVI is high in patients taking hemodialysis therapy [34, 35].

4) Metabolic Syndrome

CAVI was high in metabolic syndrome. And, body weight reduction improved CAVI in obese patients on metabolic syndrome as well as reduction of risk factors [36].

5) Cerebral Infarction

CAVI was related with cerebrovascular accidents [37].

6) Coronary Risk Factors (Diabetes Mellitus, Dyslipidemia, Obesity)

CAVI is reported to be high in patients with diabetes mellitus [28, 29, 30, 38, 39]. Recent studies have shown that insulin therapy decreases CAVI, accompanying with lowered blood glucose level [36]. Glimepiride decreased CAVI accompanied with improved glucose level [40]. CAVI decreased by diphasic insulin aspart30/70[41].

CAVI is not so closely related with hypercholesterolemia as with diabetes mellitus [28, 39, 54]. However, some reports showed that CAVI is related to LDL-cholesterol level and also to cholesterol/HDL- cholesterol ratio [21]. Soska et al. [42] reported that CAVI was not necessarily high in heterozygous familiar hypercholesterolemic patients. Initial lipidosis induced by infiltration of LDL might soften the arterial wall, and when the complicated lesion occurred, CAVI might increase. Cholesterol lowering agents such as pitavastatin [43], ezetimibe [44] and triglyceride-lowering agent, eicosapentaenoic acid [45] were reported to decrease CAVI.

7) Weight Control and Others

Weight reduction through diet and exercise therapy over a 3-month period decreased CAVI values, significantly [36]. CAVI was improved by weight reduction using formula diet [46].

CAVI was high in smoking group, and decreased by stopping smoking [23, 47] CAVI was reported to be elevated in the patients with sleep apnea syndrome [48] and decreased by continuous positive airway pressure treatment [49].

Above results might suggest that the CAVI could be a good maker of arterial stiffness, and also is a marker of controlling the coronary risk factors (Refer to Tables 11,22).

Table 2.
Improving Factor or Treatment for CAVI

Kubota [50] showed that high CAVI group (10>) showed high incidence of heart disease and cerebrovascular accidents in 3 years.

2. CAVI AS A MARKER OF SMOOTH MUSCLE CELL CONTRACTURE

The factors regulating CAVI were composed not only of organic stiffness such as collagen or elastin, but also of smooth muscle cell contracture. Those were shown by the studies using α1-aderenoceptor blocker, doxazosin, which is a dilator of peripheral artery as shown in Fig. (22,BB) [25]. CAVI was decreased as blood pressure decreased for about 4 hours, when doxazosin was administered to healthy men, as stated before.

CAVI was reportedly decreased by anesthesia, although not significantly [51]. It is interesting that vasomoter nerve function influencing the stiffness of arterial wall could be monitored with CAVI.

Beraprost sodium (beraprost) is active prostaglandin I2(PGI2) analogue with vasodilatory, antiplatelet and cytoprotective effects. Recently, Takahashi reported that beraprost sodium, PGI2 analogue, decreased CAVI without blood pressure lowering effect as shown in Fig. (33). [52].

Fig. (3)
Effects of beraprost administration on CAVI(Ref 52). Vasodilator beraprost(40 µg) was orally administered, and CAVI and blood pressure was measured every hour. Blood pressure was not changed, but CAVI decreased, but baPWV was not. These results ...

CAVI was correlated with flow-mediated dilatation of the artery [53]. Those results might indicate that CAVI is reflecting endothelial dysfunction, in which NO synthesis is disturbed.

Above these results support the idea that CAVI reflects the contracture of arterial smooth muscle cells controlled by cathecholamines, prostacyclin (PGI2), and NO synthesis in endothelial cells, in addition to organic stiffness.

3. BLOOD PRESSURE AND CAVI

1) Hypertension and CAVI in Clinical Observation (Table (Table11)

CAVI is not affected by blood pressure at the time of measurement [20, 24, 57]. Therefore, the real effect of blood pressure on the proper arterial wall stiffness can be evaluated with CAVI.

There were many papers reporting that CAVI showed high values in patients with hypertension [36, 38, 54-56] These reports were the first to demonstrate that the real effect of hypertension on the stiffness of arterial wall. But, there were also a few reports describing that there was no correlation between CAVI and blood pressure [30, 57]. And the contradictory results were obtained only by using CAVI, not by PWV.

Interestingly, when sunitinib maleate, which is interferes with the growth of cancer cells and raises blood pressure as a side effect, was administered to a patient, the increase of CAVI was observed before blood pressure increased [58]. This finding suggests that CAVI may reflect the stress to the artery induced by sunitinib maleate before hypertension occurs. Recently, Yoshida reported that CAVI was high in pregnant women complicated with preeclampsia [59]. This report also suggested that CAVI monitoring in pregnant women may be helpful to detect the preeclampsia.

2) Antihypertensive Agents and CAVI

Several papers reported the effect of antihypertensive agents on CAVI (Table 33). The decreasing rates of blood pressure by those agents are not necessarily be correlated with improvement rate of CAVI.

Table 3.
Anti-hypertensive Agents and CAVI

(1) Calcium Channel Blockers

Calcium channel blocker (CCB) is one of the most useful antihypertensive agents. However, it is known that some of CCB have the activating action of the renin-angiotensin system (RAS) or catecholamine system as an unfavorable characteristic. And, there are several types such as L-channel blocker type. T-channel blocker type and N-channel blocker type. Amlodipine is known to be a L-channel blocker type. Kurata et al. reported that amlodipine decreased CAVI ( n= 10, 24 week) [60]. Miyashita et al. reported that the decrease by amlodipine was a little, and not significant [61].

Sasaki et al. [62] compared the effects of efonidipine, T-channel blocker, and of amlodipine (L-channel blocker). The blood pressures were reduced by almost same rates (Fig. 44). But, CAVI was significantly reduced by efonidipine, but not by amlodipine. So, it is suggested that various types of Ca channel blockers had their own properties on arterial wall stiffness.

Fig. (4)
The effects of efonidipine and amlodipine on Blood pressure and CAVI (Ref 62). Efonidipine and amlodipine were CCBs. As shown in upper panel, blood pressures were decreased at almost same ratios. But, CAVI decreased much more by efonidipine than amlodipine. ...

It is very interesting point whether CAVI can differentiate the effects of different types of calcium channel blockers or not.

(2) Angiotensin II Receptor Antagonists and Angiotensin Converting Enzyme Inhibitors

Renin angiotensin aldosterone system is very important regulator of blood pressure. As for angiotensin II receptor antagonists (ARB), there were several reports. Telmisartan were reported to decrease CAVI [63]. Uehara [64] reported that candesartan reduced CAVI most among candesartan, telmisartan and losartan. Bukuda [65] studied the effect of candesartan comparing with calcium channel blockers (CCBs). They showed that blood pressure decreased significantly in both groups and the rates were not different in both group, but, candesartan significantly reduced CAVI, but not CCBs. These results were almost consistent with the studies on amlodipine and olmesartan by Miyashita et al. [61]. The blood pressures were decreased at same rate, but CAVI was decreased significantly only by olmesartan.

As for prognosis of the treatments for hypertension, angiotensin 2 receptor antagonists or angiotensinogen converting enzyme inhibitor is reported to have better effect on the prognosis of cardiovascular diseases than calcium channel blockers [66]. The coincidence of the superiority of ARB to CCBs in the prospective mass study for long term, and in simple study using CAVI for short time, is interesting and important. Much attention should have to be paid to the effects of antihypertensive agents on CAVI in terms of the prognosis of cardiovascular events.

(3) Thiazide

Diuretics are known to decrease blood pressure, but may exacerbate insulin resistance. Real effects of diuretics on arterial wall stiffness have not been done. There were no reports available to obtain the conclusion.

But, the combination of olmesartan and azelnidipine has advantages over the combination of olmesartan and thiazide with respect to CAVI in patients with moderate hypertension [67]. It might suggest that azelnidipine improved CAVI, but thiazide did not change CAVI.

A tablet combining losartan and hydrochlorothiazide has been found to decrease CAVI [68]. Both agents might compensate each other to improve CAVI.

(4) Other Antihypertensive Agents (α Blocker, β Blocker, Spironolactone)

Now, there were no reports available concerning the effects of α blocker, β blocker, and spironolactone on CAVI for long term. But, above data might suggest that CAVI might discriminate the effects of those antihypertensive agents on arterial stiffness in addition to blood pressure itself.

CONCLUSION

Future of CAVI in the Hypertension Research - (Fig. (Fig.55)

It is almost established that CAVI is reflecting the arteriosclerotic change, and also smooth muscle cell contracture. Blood pressure control system were involving many factors such as cardiac output, arterial compliance and circulating blood volume. Among them, CAVI might be reflecting compliance. The analysis of the pathogenesis of hypertension and also the prognosis of the hypertension control might be more adequately evaluated with monitoring CAVI.

CAVI may become useful index to evaluate the real effects of blood pressure control on the arteries.

Fig. (5)
The role of CAVI as a resistance or compliance of the artery and a surrogate marker of arteriosclerosis. CAVI might reflect the resistance or compliance of the artery, in addition to arteriosclerotic stiffness. Namely, CAVI reflects the vascular function, ...

ACKNOWLEDGEMENTS

We greatly appreciate Dr. Oyama, Dr. Kawana, Dr. Bann, Dr. Nagumo and Dr. Yamaguti in the department of internal medicine of Sakura Hospital, Toho University for their cooperation in conducting research on CAVI. We sincerely acknowledge the staffs in Functional Physiological Division of Sakura Hospital, Toho University for the high quality of technical examination.

CONFLICT OF INTEREST

The author(s) confirm that this article content has no conflict of interest.

REFERENCES

1. Asmar R. Pulse wave velocity principles and measurement 25-55. In: Asmar R, O’Rourke MF, Safar M, editors. Arterial stiffness and pulse wave velocity. Amsterdam: Elsevier; 1999.
2. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol. 2003;23:554–566. [PubMed]
3. Mattace-Raso FU, vanderCammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113:657–663. [PubMed]
4. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness definitions and reference values. Am J Hypertens. 2002;15:426–444. [PubMed]
5. Koizumi M, Shimizu H, Shimomura K, et al. Relationship between hyperinsulinemia and pulse wave velocity in moderately hyperglycemic patients. Diabetes Res Clin Pract. 2003;62:17–21. [PubMed]
6. Avest E, Holewijn S, Bredie SJ, vanTits LJ, Stalenhoef AF, deGraaf J. Pulse wave velocity in familial combined hyperlipidemia. Am J Hypertens. 2007;20:263–269. [PubMed]
7. Tanaka H, Munakata M, Kawano Y, et al. Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens. 2009;27:2022–2027. [PubMed]
8. Lemogoum D, Flores G, Vanden AbeeleW, et al. Validity of pulse pressure and augmentation index as surrogate measures of arterial stiffness during beta-adrenergic stimulation. J Hypertens. 2004;22:511–517. [PubMed]
9. Asmar R, Benetos SA, Topuchian J, et al. Assessment of arterila distensability by autmatic pulse wave velosity measurment: Validation and clinical application studies. Hypertension. 1995;26:485–490. [PubMed]
10. Kimoto E, Shoji T, shinohara K, et al. Preferential stiffening of central over peripheral arteries intype 2 diabetes mellitus. Diabetes. 2003;52:448–452. [PubMed]
11. Yamashina A, Tomiyama H, Takeda K, et al. Validity reproducibility and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res. 2002;25:359–364. [PubMed]
12. Kim HJ, Nam JS, Park JS, et al. Usefulness of brachial-ankle pulse wave velocity as a predictive marker of multiple coronary artery occlusive disease in Korean type 2 diabetes patients. Diabetes Res Clin Pr. 2009;85:30–34. [PubMed]
13. Seo WW, Chang HJ, Cho I, et al. The value of brachial-ankle pulse wave velocity as a predictor of coronary artery disease in high-risk patietns. Korean Circ J. 2010;40:224–229. [PMC free article] [PubMed]
14. Alvim RD, Santos PC, Dias RG, et al. Association between the C242T polymorphism in the p22phox gene with arterial stiffness in the Brazilian population. Physiol Genomics. 2012;44:587–592. [PubMed]
15. Rezai MR, Wallace AM, Sattar N, Finn JD, wu FC, Cruickshank JK. Ethnic differences in aortic pulse wave velosity occur in the descending aorta and may be related to vitamin D. Hypertension. 2100;58:247–253. [PubMed]
16. Nye ER. The effect of blood pressure alteration on the pulse wave velocity. Br Heart J. 1964;266:261–265. [PMC free article] [PubMed]
17. VanBortel LM, Duprez D, Starmans-Kool MJ, et al. Clinical applications of arterial stiffness, Task Force III: recommendations for user procedures. Am J Hypertens. 2002;15:445–452. [PubMed]
18. Hayashi K, Handa H, Nagasawa S, Okumura A, Moritake K. Stiffness and elastic behavior of human intracranial and extracranial arteries. J Biomech. 1980;13:175–184. [PubMed]
19. Kawasaki T, Sasayama S, Yagi S. Noninvasive assessment of the age related changes in stiffness of major branches of the human arteries. Cardiovascular Res. 1987;21:678–687. [PubMed]
20. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter Cardio-ankle vascular index (CAVI) J Atheroscler Thromb. 2006;13:101–107. [PubMed]
21. Takaki A, Ogawa H, Wakeyama T, et al. Cardio-ankle vascular index is a new noninvasive parameter of arterial stiffness. Circ J. 2007;71(11 ):1710–1714. [PubMed]
22. Satoh N, Shimatsu A, Kato Y, et al. Evaluation of the cardio-ankle vascular index a new indicator of arterial stiffness independent of blood pressure in obese and metabolic syndrome. Hypertension Res. 2008;31:1921–1930. [PubMed]
23. Kubozono T, Miyata M, Ueyama K, et al. Clinical significance and reproducibility of new arterial distensability Index. Circ J. 2007;71:89–94. [PubMed]
24. Shirai K, Song M, Suzuki J, et al. Contradictory effects of β1 - and α1- aderenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI) -the independency of CAVI from blood pressure. J Atheroscler Thromb. 2011;18:49–55. [PubMed]
25. Namekata T, Suzuki K, Ishizuka N, Shirai K. Establishing baseline criteria of cardio-ankle vascular index as a new indicator of arteriosclerosis a cross-sectional study. BMC Cardiovas Disord. 2011;11:51. [PMC free article] [PubMed]
26. Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H. ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J. 2008;72:598–604. [PubMed]
27. Bramwell JC, Hill AV. Velocity of the pulse wave in man. Proc Roy Soc. 1922:298–306.
28. Izuhara M, Shioji K, Kadota Y, et al. Rekationship of cardiovasular index to carotid and coronary arteriosclerosis. Circ J. 2008;72:1762–1767. [PubMed]
29. Miyoshi T, Doi M, Hirohata S, et al. Cardio-ankle vascular index is independently associated with the severity of coronary atherosclerosis and left ventricular function in patients with ischemic heart disease. J Atheroscler Thromb. 2010;17:249–258. [PubMed]
30. Horinaka S, Yabe A, Yagi H, et al. Comparison of atherosclerotic indicators between cardio ankle vascular index and brachial ankle pulse wave velocity. Angiology. 2009;60:468–476. [PubMed]
31. Sairaku A, Eno S, Hondo T, et al. Head-to-head comparison of the cardio-ankle vascular index between patients with acute coronary syndrome and stable angina pectoris. Hypertens Res. 2010;33:1162–1166. [PubMed]
32. Kubozono T, Miyata M, Ueyama K, et al. Association between arterial stiffness and estimated glomerular filtration rate in the Japanese general population. J Atheroscler Thromb. 2009;16:840–845. [PubMed]
33. Nakamura K, Iiduka T, Takahashi M, et al. Association between cardio-ankle vascular index and serum cystain c levels in patients with cardiovascular risk factor. J Atheroscler Thromb. 2009;16:371379–370. [PubMed]
34. Ueyama K, Miyata M, Kubozono T, et al. Noninvasive indices of arterial stiffness in hemodialysis patients. Hypertens Res. 2009;32:716–720. [PubMed]
35. Ichihara A, Yamashita N, Takemitsu T, et al. Cardio-ankle vascular index and ankle pulse wave velocity as a marker of arterial fibrosis in kidney failure treated by hemodialysis. Am J Kidney Dis. 2008;52:947–955. [PubMed]
36. Satoh-Asahara N, Suganami T, Majima T, et al. and the Japan Obesity and Metabolic Syndrome Study (JOMS) Group Urinary Cystatin C as a Potential Risk Marker for Cardiovascular Disease and Chronic Kidney Disease in Patients with Obesity and Metabolic Syndrome. Clin J Am Soc Nephrol. 2011;6:265–273. [PubMed]
37. Suzuki J, Sakakibara R, Tomaru T, et al. Stroke and Cardio-ankle Vascular Stiffness Index. J Stroke Cerebrovasc Dis. Epub August 19. [PubMed]
38. Namekata T, Suzuki K, Ishizuka N. Association of Cardio-Ankle Vascular Index with Cardiovascular Disease Risk Factors and Coronary Heart Disease among Japanese Urban Workers and their Families. J Clinic Experiment Cardiol. 2012:S1–003.
39. Ibata J, Sasaki H, Kakimoto T, et al. Cardio-ankle vascular index measures arterial wall stiffness independent of blood pressure. Diabetes Res Clin Pract. 2008;80:265–270. [PubMed]
40. Nagayama D, Saiki A, Endo K, et al. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract. 2010;64:1796–1801. [PubMed]
41. Ohira M, Endo K, Oyama T, et al. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism. 2011;60:78–85. [PubMed]
42. Soska V, Dobsak P, Dusek L, et al. Cardio-Ankle Vascular Index in Heterozygous Familial Hypercholesterolemia. J Atheroscler Thromb. 2012;19:453–461. [PubMed]
43. Miyashita Y, Endo K, Saiki A, et al. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb. 2009;16:539–545. [PubMed]
44. Miyashita Y, Endo K, Saiki A, et al. Effect of ezetimibe monotherapy on lipid metabolism and arterial patients. J Atheroscler Thromb. 2010;17:1070–6. [PubMed]
45. Satoh N, Shimatsu A, Kotani K, et al. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res. 2009;32:1004–1008. [PubMed]
46. Nagayama D, Endo K, Ohira M, et al. Effects of body weight reduction on cardio-ankle vascular index (CAVI) Ob Res Clin Prac . Epub October 5. [PubMed]
47. Noike H, Nakamura K, Sugiyama Y, et al. Changes in cardio-ankle vascular index in smoking cessation. J Atheroscler Thromb. 2010;17:517–525. [PubMed]
48. Kumagai T, Kasai T, Kato M, et al. Establishment of the cardio-ankle vascular index in patients with obstructive sleep apnea. Chest. 2009;136:779–786. [PubMed]
49. Kasai T, Inoue K, Kumagai T, et al. Plasma pentraxin3 and arterial stiffness in men with obstructive sleep apnea. Am J Hypertens. 2011;24:401–407. [PubMed]
50. Kubota Y, Maebuchim d, Takei M, et al. Cardio-Ankle Vascular Index is a predictor of cardiovascular events. Artery Res. 2011;5:91–96.
51. Kim B, Takada K, Oka S, Misaki T. Influence of blood pressure on cardio-ankle vascular index (CAVI) examined based on percentage change during general anesthesia. Hypertens Res. 2011;34:779–783. [PubMed]
52. Takahashi M, Shiba T, Hirano K, Hitsumoto T, Shirai K. Acute Decrease of Cardio-Ankle Vascular Index with the Administration of Beraprost Sodium. J Atheroscler Thromb. 2012;19:479–484. [PubMed]
53. Endo K, Saiki A, Ohira M, Miyashita Y, Shirai K. Cardio-ankle vascular index may reflect endothelial function. Int J Clin Pract. 2011;65:1200–1201. [PubMed]
54. Okura T, Watanabe S, Kurata M, et al. Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension. Hypertens Res. 2007;30:335–340. [PubMed]
55. Sakane K, Miyoshi T, Doi T, et al. Assocoation of new arterial stiffness parameter the cardio-ankle vascular index with left ventricular diastolic function. J Atheroscler Thromb. 2008;15:261–268. [PubMed]
56. Kadota K, Takamura N, Aoyagi K, et al. Availability of cardio-ankle vascular index (CAVI) as a screening tool for atherosclerosis. Circ J. 2008;72:304–308. [PubMed]
57. Takaki A, Ogawa H, Wakeyama T, et al. Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness. Hypertens Res. 2008;31:1347–1355. [PubMed]
58. Masugata H, Senda S, Himoto T, et al. Early detection of hypertension in a patient treated with sunitinib by measuring cardio-ankle vascular index. Tohoku J Exp Med. 2009;218:115–119. [PubMed]
59. Yoshida a, Suhiyama T, Sagawa N. Assessment of the cardioankle vascular index in pregnant women complicated with hypertensive disorders. ISRN Obstet Gynecol 2011. 2011:919816. [PMC free article] [PubMed]
60. Kurata M, Okura T, Watanabe S, et al. Effects of amlodipine and candesartan on arterial stiffness estimated by cardio-ankle vascular index in patients with essential hypertension A 24-week study. Curr Ther Res. 2008;69:412–422. [PMC free article] [PubMed]
61. Miyashita Y, Saiki A, Endo K, et al. Effects of olmesartan an angiotensin II receptor blocker and amlodipine a calcium channel blocker on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb. 2009;16:621–626. [PubMed]
62. Sasaki H, Saiki A, Endo K, et al. Protective effects of efonidipine, a T- and L-type calcium channel blocker on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. J Atheroscler Thromb. 2009;16:568–75. [PubMed]
63. Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A, Murohashi-Bokuda K, Itoh H. Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. Kidney Blood Press Res. 2010;33:304–312. [PubMed]
64. Uehara G, Takeda H. Relative effects of telmisartan candesartan and losartan on alleviateing arterial stiffnes inpatients with hypertension complicated by diabetes mellitus An evaluation using the cardiovascular index. J Inter Medical Res. 2008;36:1094–1102. [PubMed]
65. Bukuda IchiharaA, Sakoda M, Mito A, Kinouchi K, Itoh H. Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome. Vasc Health Risk Manag. 2010;6:571–578. [PMC free article] [PubMed]
66. Ogihara T, Fujimoto A, Nakao K, Saruta T. ARB candesartan and CCB amlodipine in hypertensive patients the CASE-J trial. Ex Revf Cardiovasc Ther. 2008;6(9 ):1195–1201. [PubMed]
67. Ishimitsu T, Numabe A, Masuda T, et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res. 2009;32:962–968. [PubMed]
68. Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A, Itoh H. Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. Hypertens Res. 2009;32:1143–1147. [PubMed]

Articles from Bentham Open Access are provided here courtesy of Bentham Science Publishers